Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients

European Journal of Paediatric Neurology

Volumn 12, Issue 4, 2008, Pages 334-341

  de Bont, Judith M ^a   Vanderstichele, Hugo ^b   Reddingius, Roel E ^a   Pieters, Rob ^a   van Gool, Stefaan W ^c  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b INNOGENETICS   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Amyloid(1 42); Cerebrospinal fluid; Hydrocephalus; Neurodegeneration; p Tau(181P); Pediatric brain tumor; t Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADOLESCENT; ARTICLE; BRAIN TUMOR; CANCER PATIENT; CEREBROSPINAL FLUID; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; FEMALE; HUMAN; HYDROCEPHALUS; LUMBAR PUNCTURE; MALE; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; AGE FACTORS; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROCEPHALUS; IMMUNOASSAY; INFANT; MALE; MICROSPHERES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 43549110084     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2007.09.007     Document Type: Article

References (55)

1. Andreasen N., Minthon L., Clarberg A., et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 53 (1999) 1488-1494
2. Andreasen N., Minthon L., Davidsson P., et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58 (2001) 373-379
3. Galasko D., Chang L., Motter R., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55 (1998) 937-945
4. Hulstaert F., Blennow K., Ivanoiu A., et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52 (1999) 1555-1562
5. Shoji M., Matsubara E., Kanai M., et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 158 (1998) 134-140
6. Motter R., Vigo-Pelfrey C., Kholodenko D., et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38 (1995) 643-648
7. Galasko D. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease. J Neural Transm Suppl 53 (1998) 209-221
8. Kanai M., Matsubara E., Isoe K., et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 44 (1998) 17-26
9. Tapiola T., Pirttila T., Mikkonen M., et al. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett 280 (2000) 119-122
10. Arai H., Morikawa Y., Higuchi M., et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 236 (1997) 262-264
11. Green A.J., Harvey R.J., Thompson E.J., and Rossor M.N. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett 259 (1999) 133-135
12. Riemenschneider M., Wagenpfeil S., Diehl J., et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 58 (2002) 1622-1628
13. Fabre S.F., Forsell C., Viitanen M., et al. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations. Exp Neurol 168 (2001) 413-418
14. Hampel H., and Teipel S.J. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord 17 (2004) 350-354
15. Bartosik-Psujek H., and Archelos J.J. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 251 (2004) 414-420
16. Bartosik-Psujek H., and Stelmasiak Z. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. J Neural Transm (2005)
17. Brettschneider J., Maier M., Arda S., et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler 11 (2005) 261-265
18. Otto M., Wiltfang J., Tumani H., et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 225 (1997) 210-212
19. Buerger K., Otto M., Teipel S.J., et al. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging 27 (2006) 10-15
20. Cepek L., Steinacker P., Mollenhauer B., et al. Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 19 (2005) 376-382
21. Otto M., Esselmann H., Schulz-Shaeffer W., et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54 (2000) 1099-1102
22. Riemenschneider M., Wagenpfeil S., Vanderstichele H., et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 8 (2003) 343-347
23. Sjogren M., Davidsson P., Wallin A., et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 13 (2002) 112-118
24. Hesse C., Rosengren L., Andreasen N., et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297 (2001) 187-190
25. Shiiya N., Kunihara T., Miyatake T., et al. Tau protein in the cerebrospinal fluid is a marker of brain injury after aortic surgery. Ann Thorac Surg 77 (2004) 2034-2038
26. Andersson L., Blennow K., Fuchs D., et al. Increased cerebrospinal fluid protein tau concentration in neuro-AIDS. J Neurol Sci 171 (1999) 92-96
27. Tisell M., Tullberg M., Mansson J.E., et al. Differences in cerebrospinal fluid dynamics do not affect the levels of biochemical markers in ventricular CSF from patients with aqueductal stenosis and idiopathic normal pressure hydrocephalus. Eur J Neurol 11 (2004) 17-23
28. Kudo T., Mima T., Hashimoto R., et al. Tau protein is a potential biological marker for normal pressure hydrocephalus. Psychiatry Clin Neurosci 54 (2000) 199-202
29. Holownia A., Trofimiuk E., Krawczuk-Rybak M., et al. Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol. Acta Haematol 112 (2004) 222-224
30. van Gool S.W., van Kerschaver E., Brock P., et al. Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. Leukemia 14 (2000) 2076-2084
31. Vanderstichele H, Demeyer L, De Roo K, et al. Standardized multiparameter quantification of biomarkers for Alzheimer's disease in cerebrospinal fluid. Medimond S.r.l.; 2005. p. 183-9.
32. Olsson A., Vanderstichele H., Andreasen N., et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51 (2005) 336-345
33. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310 (2001) 173-186
34. van Gool S.W., De Meyer G., van de Voorde A., et al. Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. Neurotoxicology 25 (2004) 471-480
35. Lofberg H., Grubb A.O., Sveger T., and Olsson J.E. The cerebrospinal fluid and plasma concentrations of gamma-trace and beta2-microglobulin at various ages and in neurological disorders. J Neurol 223 (1980) 159-170
36. Burkhard P.R., Fournier R., Mermillod B., et al. Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations. Clin Chem Lab Med 42 (2004) 396-407
37. Sjogren M., Vanderstichele H., Agren H., et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 47 (2001) 1776-1781
38. Reijn T.S., Rikkert M.O., van Geel W.J., et al. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clin Chem 53 (2007) 859-865
39. Binder L.I., Frankfurter A., and Rebhun L.I. The distribution of tau in the mammalian central nervous system. J Cell Biol 101 (1985) 1371-1378
40. Spillantini M.G., and Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 21 (1998) 428-433
41. Del Bigio M.R. Neuropathological changes caused by hydrocephalus. Acta Neuropathol (Berl) 85 (1993) 573-585
42. Del Bigio M.R. Cellular damage and prevention in childhood hydrocephalus. Brain Pathol 14 (2004) 317-324
43. McAllister II J.P., and Chovan P. Neonatal hydrocephalus. Mechanisms and consequences. Neurosurg Clin N Am 9 (1998) 73-93
44. Ding Y., McAllister II J.P., Yao B., et al. Axonal damage associated with enlargement of ventricles during hydrocephalus: a silver impregnation study. Neurol Res 23 (2001) 581-587
45. Weller R.O., and Williams B.N. Cerebral biopsy and assessment of brain damage in hydrocephalus. Arch Dis Child 50 (1975) 763-768
46. Rostasy K., Withut E., Pohl D., et al. Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol 20 (2005) 822-825
47. Andreasen N., Vanmechelen E., van de Voorde A., et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry 64 (1998) 298-305
48. Ishiguro K., Ohno H., Arai H., et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 270 (1999) 91-94
49. Blennow K., Vanmechelen E., and Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24 (2001) 87-97
50. Kohnken R., Buerger K., Zinkowski R., et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 287 (2000) 187-190
51. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 16 (1993) 460-465
52. Blennow K., and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2 (2003) 605-613
53. Blennow K., and Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull 61 (2003) 235-242
54. Parnetti L., Lanari A., Amici S., et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 22 (2001) 77-78
55. Schoonenboom N.S., Mulder C., Vanderstichele H., et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 51 (2005) 189-195